# Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

> **NCT06421311** · — · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 176 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** nivolumab

## Key facts

- **NCT ID:** NCT06421311
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2024-07-30
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-04-04
- **Target enrollment:** 176 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421311, "Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06421311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*